Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Detailed summary
Study did not meet key efficacy measures or internal hurdle rate for continued development Systemic mast cell depletion observed, consistent with prior studies, as evidenced by significant reduction in serum tryptase Favorable safety and tolerability demonstrated, consistent with prior studies BLA submission for barzolvolimab in CSU anticipated in 2027Phase 3 barzolvolimab cold urticaria and symptomatic…
HAMPTON, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company's Phase 2 study of barzolvolimab in moderate to severe atopic dermatitis (AD). Barzolvolimab, a first-in-class humanized monoclonal antibody with a novel mechanism of action that uniquely targets the KIT receptor and depletes mast cells, is being studied across multiple indications where mast cells are implicated in the disease pathology. The primary endpoint of the Phase 2 AD study, the percent change from baseline in the weekly average of the daily Peak Pruritus Numerical Rating Scale (PP-NRS) score at Week 16 compared to placebo, and key secondary endpoints were not met.
"Celldex is leading the exploration of mast cell science to understand the contribution of mast cells to various diseases and how targeted mast cell depletion can best be implemented to improve the lives of patients," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. "We have delivered best in disease data in chronic spontaneous urticaria, cold urticaria and symptomatic dermographism while also increasing our understanding of which diseases, like atopic dermatitis, might not be primarily driven by mast cells. We are thankful to the patients and investigators who have played an important role in furthering this science.
In the Phase 2 AD study, 131 patients from 28 US-based centers were randomized in a 1:1:1 ratio to receive subcutaneous injections of barzolvolimab at either 150 or 300 mg every 4 weeks after an initial loading dose of 450 mg or placebo during a 16-week placebo-controlled treatment phase. Patients then entered a 16-week active treatment period, in which patients in the 150 mg and 300 mg dose groups continued to receive barzolvolimab at the same dose, while patients randomized into the placebo arm were re-randomized into one of the two active treatment arms.
Opening of the article, excerpted from Yahoo Finance. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)




